Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.840.02%
QQQ
717.920.06%
BTC/USD
78524.380.7155%
DIA
527.880.03%
GLD
399.210.13%
TLT
82.130.09%

Solid Biosciences Inc (SLDB) Stock Price, Quote, News & History

SLDBNASDAQ
Trade with Public
Trade with Public
$9.93
-0.32-3.12%
At close: Sep 8, 5:00 PM EST
$9.89
-0.04-0.4%
After Hours: 6:22 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Solid Biosciences (SLDB) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$10.00
Close
$9.93
Volume / Avg.
742.82K / 1.56M
Day Range
$9.58 - $10.09
52 Wk Range
3.79 - 11.45
Market Cap
$1.06B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
56
Short Interest
17.62%
Days to Cover
19.61

Recent Solid Biosciences Inc News

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom target.
Avi Kapoor

Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
Avi Kapoor

Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
Avi Kapoor

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.
Avi Kapoor

Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned

Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious despite promising results and FDA plans.
Vandana Singh

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-186.84M
Investing Cash Flow (TTM)
-87.09M
Financing Cash Flow (TTM)
293.82M
Free Cash Flow (TTM)
-187.81M
Capital Expenditure (TTM)
-965.00K
Net Change in Cash (TTM)
19.88M

Analyst Trends and Forecast

8
Mar
3
May
1
Jun
2
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$741.54M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
2.94
Earnings Yield % (TTM)
-18.44%
Earnings Yield % (FWD)
-15.51%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$3.49

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$446.00K
Total Cash
$159.39M
Debt to Equity
0.05
Issuance of Debt (TTM)
-$446.00K
Repayment of Debt (TTM)
-$446.00K

Key Statistics

Open
$10.00
Close
$9.93
Volume / Avg.
742.82K / 1.56M
Day Range
$9.58 - $10.09
52 Wk Range
3.79 - 11.45
Market Cap
$1.06B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
56
Short Interest
17.62%
Days to Cover
19.61

About

Sector
Health Care
Industry
Biotechnology
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Solid Biosciences (SLDB) stock?

A

You can purchase shares of Solid Biosciences (NASDAQ:SLDB) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Solid Biosciences (SLDB) competitors?

Q

What is the forecast, or price target, for Solid Biosciences (SLDB) stock?

A

Solid Biosciences has a consensus price target of $17.40.

Q

What is the current price for Solid Biosciences (SLDB)?

A

The stock price for Solid Biosciences (NASDAQ: SLDB) is $9.89 last updated September 8, 2026 at 6:22 PM EDT.

Q

Does Solid Biosciences (SLDB) pay a dividend?

A

There are no upcoming dividends for Solid Biosciences.

Q

When is Solid Biosciences (NASDAQ:SLDB) reporting earnings?

A

Solid Biosciences does not have any upcoming earnings scheduled.

Q

Is Solid Biosciences (SLDB) going to split?

A

There is no upcoming split for Solid Biosciences.

Q

What sector and industry does Solid Biosciences (SLDB) operate in?

A

Solid Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved